Spend less to achieve more: Economic analysis of intermittent versus continuous cetuximab in KRAS wild-type patients with metastatic colorectal cancer

$1.00

Licensing Options

Clear

Category: Metastatic colorectal cancer

Tags: Model 18

All your purchased models will be available under your account under “Dashboards”

Disease Area (Primary)

Metastatic colorectal cancer

Disease Area (Secondary)

–

First Developed

06/13/2022

Last Developed

–

Software Used

Microsoft Excel

Model Sponsor

Academic institution

Intervention

intermittent_vs_continuous_cetuximab

Model Validation Score

65 %

Coming Soon In Phase II: You will be able to pay a fee to download the CADTH Tool for your model which includes subaggregated scores.

Results

Intermittent reduced costs by £35,763 (PSM) or £30.189 (Markov) per patient annually while preserving Rx efficacy and QoL

Conclusion

Cost savings by treatment de-escalation

Source File(s)

Model:

Download Model File

Publication File:

Publication File 1:

Publication File 2:

Publication File 3:

Publication File 4:

Download Publication File

No link submitted.

Model Review

Only visible for the model owner

Summary

Validation Score

65 %

Internal Comments

–

Spend less to achieve more: Economic analysis of intermittent versus continuous cetuximab in KRAS wild-type patients with metastatic colorectal cancer

Model:

Model Script 2 :

Model Script 3 :

Model Script 3 :

Publication File:

Publication File 1:

Publication File 2:

Publication File 3:

Publication File 4:

Code file 1 :

Code file 2 :

Code file 3 :

Code file 4 :

Non-Model Script 1 :

Non-Model Script 2 :

Non-Model Script 3 :

Non-Model Script 4 :

Data File 1 :

Data File 2 :

Data File 3 :

Data File 4 :

Document 1 :

Document 2 :

Document 3 :

Document 4 :

Model Review

Summary

Validation Score

Internal Comments